Elan will retain ownership of assets and control over each program.

Elan and contract research organization PPD have forged a global business collaboration establishing the latter as Elan’s primary service provider for the development of its pipeline. Elan will retain ownership of all its assets and control over each program, and will leverage PPD’s capabilities in areas spanning project and data management, biostatistics, regulatory, clinical and medical monitoring, quality assurance, and pharmacovigilance.  

“Establishing this strategic collaboration wtih PPD will enable Elan to accelerate the progression of our science into the clinical development setting in a rapid and global fashion,” notes Eliseo Salinas, Elan’s CMO, executive vp and head of development. “The ability to fluidly access additional expertise and execution capability on a global scale will complement our internal talent and may enable us to move multiple programs forward in a parallel manner.”

PPD is a global CRO providing drug discovery, development, and lifecycle management services. The firm has offices in 43 countries.

Previous articleNovartis to Assess Quanterix’ Single Molecule Array Platform for Diagnostic Use
Next articleVertex Plans EU and U.S. Filing for CF Therapy This Year Following Phase III Success